propafenone hcl- propafenone hydrochloride tablet, film coated
ethex - propafenone hydrochloride (unii: 33xch0hocd) (propafenone - unii:68iqx3t69u) - tablet, film coated - 150 mg - in patients without structural heart disease, propafenone hcl is indicated to prolong the time to recurrence of - paroxysmal atrial fibrillation/flutter (paf) associated with disabling symptoms. - paroxysmal supraventricular tachycardia (psvt) associated with disabling symptoms. as with other agents, some patients with atrial flutter treated with propafenone have developed 1:1 conduction, producing an increase in ventricular rate. concomitant treatment with drugs that increase the functional av refractory period is recommended. the use of propafenone in patients with chronic atrial fibrillation has not been evaluated. propafenone should not be used to control ventricular rate during atrial fibrillation. propafenone is also indicated for the treatment of initiation of propafenone treatment, as with other antiarrhythmics used to treat life-threatening ventricular arrhythmias, should be carried out in the hospital. propafenone, like other antiarrhythmic drugs, has not been shown to enhance survival in patients w
propafenone hydrochloride 300mg film-coated tablets
accord healthcare limited - propafenone hydrochloride - film-coated tablet - 300 milligram(s) - antiarrhythmics, class ic; propafenone
propafenone hydrochloride 150mg film-coated tablets
accord healthcare limited - propafenone hydrochloride - film-coated tablet - 150 milligram(s) - antiarrhythmics, class ic; propafenone
propafenone tablet
sanis health inc - propafenone hydrochloride - tablet - 150mg - propafenone hydrochloride 150mg - class ic antiarrythmics
propafenone tablet
sanis health inc - propafenone hydrochloride - tablet - 300mg - propafenone hydrochloride 300mg - class ic antiarrythmics
propafenone hydrochloride tablet film coated
bryant ranch prepack - propafenone hydrochloride (unii: 33xch0hocd) (propafenone - unii:68iqx3t69u) - propafenone hydrochloride 150 mg
propafenone hcl hydrochloride tablet film coated
avera mckennan hospital - propafenone hydrochloride (unii: 33xch0hocd) (propafenone - unii:68iqx3t69u) - propafenone hydrochloride 225 mg
propafenone hydrochloride tablet film coated
cardinal health - propafenone hydrochloride (unii: 33xch0hocd) (propafenone - unii:68iqx3t69u) - propafenone hydrochloride 150 mg
propafenone hydrochloride tablet film coated
mylan institutional inc. - propafenone hydrochloride (unii: 33xch0hocd) (propafenone - unii:68iqx3t69u) - propafenone hydrochloride 150 mg
propafenone hydrochloride capsule, extended release
american health packaging - propafenone hydrochloride (unii: 33xch0hocd) (propafenone - unii:68iqx3t69u) - propafenone hcl extended release capsules, usp are indicated to prolong the time to recurrence of symptomatic atrial fibrillation (af) in patients with episodic (most likely paroxysmal or persistent) af who do not have structural heart disease. usage considerations: - the use of propafenone er capsules in patients with permanent af or in patients exclusively with atrial flutter or paroxysmal supraventricular tachycardia (psvt) has not been evaluated. do not use propafenone er capsules to control ventricular rate during af. - some patients with atrial flutter treated with propafenone have developed 1:1 conduction, producing an increase in ventricular rate. concomitant treatment with drugs that increase the functional atrioventricular (av) nodal refractory period is recommended. - the effect of propafenone on mortality has not been determined [see boxed warning ]. propafenone er capsules are contraindicated in the following circumstances: - heart failure - cardiogenic shock - sinoatrial, atrioventricular